COVID-19 for Oncologists [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== COVID-19 for Oncologists ======

Findings suggest that the COVID-19 pandemic had a substantial impact on cancer patients, with several challenges specific to rural patients. A comprehensive study provided unique insights into the first 6 months of COVID-19 pandemic-related experiences and continuity of care among rural and urban cancer patients predominantly from Utah. Further research is needed to better characterize the pandemic's short- and long-term effects on rural and urban cancer patients and appropriate interventions
((Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM. Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural Health. 2022 Mar 3. doi: 10.1111/jrh.12648. Epub ahead of print. PMID: 35243690.)).

----

Handling the [[COVID-19]] pandemic in the oncological setting.
((Mussetti A, Maluquer C, Albasanz-Puig A, Gudiol C, Moreno-Gonzalez G,
Corradini P, Sureda A. Handling the COVID-19 pandemic in the oncological setting.
Lancet Haematol. 2020 Apr 1. pii: S2352-3026(20)30108-3. doi:
10.1016/S2352-3026(20)30108-3. [Epub ahead of print] PubMed PMID: 32246913.)).

Kamal et al. conducted a [[meta-analysis]] to address the outcomes in cancer patients after oncologic surgery during the COVID-19 pandemic. The primary endpoint was the COVID-19-related [[mortality rate]]. Higher [[body mass index]] was significantly and negatively associated with higher all-cause mortality and in-hospital COVID-19 [[infection]] rates. [[Male]] sex, preoperative respiratory disease, and [[smoking]] history were positively and significantly associated with increased all-cause mortality rates. Furthermore, male sex was positively and significantly associated with the COVID-19 infection rate
((Kamal M, Baudo M, Shmushkevich S, Geng Y, Hanna E, Goepfert RP, Lewis CM, Rahouma M. COVID-19 infection and its consequences among surgical oncology patients: A systematic analysis, meta-analysis and meta-regression. J Surg Oncol. 2022 Jan 11. doi: 10.1002/jso.26787. Epub ahead of print. PMID: 35014703.)).
----


[[Neuro-oncology]] Management During the [[COVID-19 Pandemic]] With a Focus on [[WHO Grade III]] and IV Gliomas.

Because of the increased risk in cancer patients of developing complications caused by the [[severe acute respiratory syndrome coronavirus 2]] (SARS-CoV-2), physicians have to balance the competing risks of the negative impact of the [[pandemic]] and the [[primary tumor]]. In this [[consensus]] statement, an international group of [[expert]]s present mitigation strategies and treatment guidelines for patients suffering from [[high-grade glioma]]s ([[HGG]]) during the [[coronavirus]] disease [[2019]] ([[COVID-19]]) [[pandemic]].

16 international experts in the treatment of HGG contributed to this consensus-based practice recommendation including neuro-oncologists, neurosurgeons, radiation -oncologists, and a medical physicist. Generally, the treatment of neuro-oncological patients cannot be significantly delayed, and initiating therapy should not be outweighed by COVID-19. We present detailed interdisciplinary treatment strategies for molecular subgroups in two pandemic scenarios, a scale-up phase, and a crisis phase.

This practice recommendation presents a pragmatic framework and consensus-based mitigation strategies for the treatment of HGG patients during the SARS-CoV-2 pandemic
((Bernhardt D, Wick W, Weiss SE, Sahgal A, Lo SS, Suh JH, Chang EL, Foote M,
Perry J, Meyer B, Vajkoczy P, Wen PY, Straube C, Pigorsch S, Wilkens JJ, Combs
SE. Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO
Grade III and IV Gliomas. Neuro Oncol. 2020 May 5. pii: noaa113. doi:
10.1093/neuonc/noaa113. [Epub ahead of print] PubMed PMID: 32369601.
)).